New York Cannabis: 519 Stores, $10.61 Flower, ~16% Capture, and the Most Transparent Failure in Legal Cannabis

New York's cannabis market generated $1.48 billion in adult-use sales through November 2025 across 519 dispensaries. Despite this, the state captures an estimated 16% of total demand. The OCM's own reports are the most analytically sophisticated in the country, and they confirm what the consumption math makes unavoidable: New York is building the infrastructure correctly while an estimated 84% of demand flows to the illicit market.

The Numbers

New York legalized adult-use cannabis under the Marihuana Regulation and Taxation Act (MRTA), signed March 31, 2021. First retail sale occurred December 29, 2022 through Conditional Adult Use Retail Dispensary (CAURD) licensees. The market operates under the Office of Cannabis Management (OCM) and Cannabis Control Board (CCB).

As of November 30, 2025:

• 519 open dispensaries as of November 30, 2025 per the OCM Annual Report (from 713 licensed retail locations; a separate CCB press release dated December 31 cites 556 open locations, likely reflecting additional openings through year-end)
• $1.48 billion adult-use retail sales YTD 2025
• $2.5 billion cumulative adult-use sales since launch
• $3.8 million annualized per store (Q3 2025)
• $32 average price per unit sold (down from $39 peak in early 2024)
• $340.6 million in taxes collected (April 2023 – November 2025)

The growth trajectory is real. Monthly sales surged from $2.2 million in January 2023 to $133.3 million in November 2024. The state opened roughly one dispensary per business day through 2025. But growth in stores and growth in capture are not the same thing.

Flower Pricing

New York's OCM reports average retail prices by package size for flower — the only major category where direct per-gram calculation is possible from official data:

Weighting by dollar share and converting to volume: $10.61 per gram weighted average for flower.

At $10.61 per gram, New York flower is more expensive than Virginia's medical monopoly and nearly triple the price of Massachusetts. This is not a tax problem — New York's adult-use tax structure is moderate by national standards: a 9% distributor excise on wholesale transfers plus a 13% retail excise (9% state + 4% local) on consumer sales, with adult-use cannabis exempt from sales tax. The effective combined burden runs ~20-22%. The medical program carries a lower 3.15% gross receipts excise. Both are well below Illinois (25-35%) and comparable to Massachusetts (~20%). This is a supply chain immaturity problem compounded by the fact that 45% of cultivators are outdoor growers competing against a consumer base accustomed to indoor-grown illicit product, and the state's Registered Organizations (legacy medical operators) are the only licensees currently authorized to grow at scale indoors.

Total Addressable Market

New York's adult population 21+ is approximately 15.4 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 2.77 million estimated consumers
• 1.012 billion grams annual demand (biologically fixed regardless of price)
• $10.73 billion dollar TAM at current $10.61/g flower pricing

Against $1.48 billion in 2025 adult-use retail sales (annualized ~$1.6B):

The OCM's own market report states the legal market has captured "less than one-fifth of the estimated total addressable demand." The consumption math confirms this — and suggests the actual figure is closer to the low end of that range.

Price Per Gram and Legal Capture

The cross-jurisdictional pattern across the markets studied is consistent: price is the strongest predictor of capture. In the dataset used here, markets under $5 out-the-door achieve full capture or better. Markets over $8 are below 50%. New York at $10.61 base price produces the capture rate the pricing predicts.

Maine is the instructive outlier — $7.57 out the door with 100% capture, driven by enforcement against the illicit market and no cheaper legal neighbor. New York has neither advantage. The illicit market operates openly (1,500+ storefronts padlocked in 2024 alone, with enforcement hampered by a court injunction in 2025), and New Jersey's legal dispensaries are accessible to millions of NYC-area consumers.

Dispensary Density and Legal Capture

New York's 519 stores serving 15.4 million adults produces a density of 3.4 per 100,000 — a dramatic improvement from the 1.7 per 100K at end of 2024, but still far below the threshold where markets achieve meaningful capture.

New York's $3.8M per store is healthy — it's right where Massachusetts sits with full capture. But the density isn't doing what density does in other markets because price hasn't compressed. In Colorado, Oregon, and Massachusetts, density forced competition that compressed flower prices below $5/g, which is where capture crosses the 100% threshold. In New York, 519 stores have driven the average unit price down only 15% (from $39 to $32) — not nearly enough to close the gap with a deeply entrenched illicit market selling comparable product at 40-60% lower prices.

The OCM's own target of 2,000 operational retailers would produce 13.0 per 100K — comparable to Maine (12.8). But density alone won't achieve Maine-level capture unless prices compress toward Maine-level pricing. The mechanism is density → competition → price compression → capture. New York is executing step one. Steps two through four haven't followed yet.

The Long Island Problem

Long Island is Rhode Island's monopoly dynamic at 10x scale. With only a handful of open dispensaries serving 2.8 million residents, the region's stores average $29.8 million annualized per store — double Rhode Island's $15M and the highest per-store figure in any market tracked. Municipal opt-outs have created artificial scarcity through zoning rather than licensing caps, but the economic outcome is identical: a small number of stores capturing monopoly rents while the majority of consumer demand flows to the illicit market or across borders into New York City dispensaries.

Queens shows a similar pattern at $6.6M/store with only 23 open locations serving a population that could support 10x that number. The Bronx ($3.0M/store) and Western NY ($2.6M/store) are at the other end — more stores relative to population, lower per-store revenue, and presumably higher capture within their regions.

The OCM tracks this regional disparity but doesn't frame it as what it is: regulatory-induced monopoly pricing at the municipal level. Long Island's $29.8M/store isn't a success metric. It's the same data point as Rhode Island's $15M — evidence that demand vastly exceeds licensed supply, with the difference captured by the illicit market.

The Illicit Market

New York's illicit cannabis market is the most visible in the country, and to OCM's credit, the agency doesn't pretend otherwise. The Enforcement Division reports its numbers transparently:

• Completed 8,055 total enforcement actions (2023-2025 combined)
• Seized $143.8 million in illicit product (2023-2025)
• Padlocked 1,500+ unlicensed storefronts in 2024
• Enforcement actions dropped from 5,215 (2024) to 2,017 (2025) after a court injunction limited inspection authority

Those numbers sound aggressive. But OCM's own market data provides the denominator that reframes them. Against an estimated $9+ billion annual illicit market, $143.8 million seized over three years represents less than 1.6% of a single year's illicit supply removed — regardless of how the seized product was priced. Seizures declined 70% year-over-year ($68.5M to $20.3M) while legal capture didn't meaningfully increase. The enforcement report itself documents repeat raids at the same locations — the Elmira operator's stores were raided in 2023 and were still operating when they were hit again in 2025.

This isn't a criticism of OCM's effort. It's a structural observation: enforcement at any plausible scale cannot solve a pricing problem. The per-store revenue decline from ~$4.0M to $3.8M tracks almost exactly with the 15% unit price compression ($39 to $32 average) — same consumer traffic, lower ticket — not with any enforcement-driven shift in illicit market share.

Maine achieves 100% capture at $6.38/g not because of superior enforcement but because the legal price leaves the illicit market with no price advantage worth the risk. New York's illicit operators can absorb infinite padlocking as long as they're selling comparable product at half the legal price. You can't enforce your way to competitive pricing. The tool OCM has isn't the wrong tool because OCM is using it badly. It's the wrong tool for a market where the legal product costs 2-3x the illicit alternative.

What the OCM Gets Right

Credit where it's due: New York's OCM produces the most analytically sophisticated cannabis market reporting in the country. The 2024 Market Report includes:

• Revenue per location by region with annualized run rates
• Revenue distribution curves showing the top 10 stores account for 25% of sales
• Population-per-dispensary benchmarking against other states
• Wholesale and retail price compression timelines across mature markets
• Product category breakdowns with pricing by package size and source

This is materially better than what most state regulators publish. The data exists to calculate everything in this analysis — the OCM just hasn't connected it to a consumption-based TAM framework or built the price-to-capture model that explains why 519 stores at $10.61/g produces 16% capture while 405 stores at $4.01/g (Massachusetts) produces 100%.

Where the Analysis Falls Short

The OCM benchmarks New York's per-capita revenue against mature markets to estimate capture. This method systematically overstates capture in expensive markets. When Colorado generates $300 per capita at $3.18/g and New York generates $95 per capita at $10.61/g, the revenue benchmark says New York captures ~32% of Colorado's mature performance. But the same gram of consumption generates 3.3x more revenue in New York. Revenue benchmarks compare dollars. The BMDE framework compares grams — because demand is biological, not economic.

The OCM's "less than one-fifth" estimate is honest by revenue-benchmark standards. The consumption math says dollar capture is closer to 16% — but that figure is inflated by legal prices running 2x the illicit market. At an estimated $5-6/g for illicit flower versus $10.61/g legal, actual volume capture is closer to 8%. The legal market is serving roughly 8% of grams consumed while collecting 16% of dollars spent — the gap is the price premium.

Recommendation #11: The Wrong Direction

The OCM's market report includes a recommendation to "regulate the use of price as a competitive differentiator" — essentially restricting discounting to prevent aggressive price competition. The stated rationale is protecting margins for small operators as the market grows.

Every data point across every jurisdiction studied shows the opposite: price compression is the mechanism that converts illicit consumers to legal consumers. Markets that compressed below $5/g final price achieved full capture. Markets that maintained high prices through limited competition or regulatory intervention maintained large illicit markets.

Restricting discounting in a market where the legal price is 2-3x the illicit price doesn't protect small operators. It protects the illicit market. The cultivators and retailers who will survive in New York are those who can compete on price, quality, and convenience against a deeply entrenched illegal supply chain. Restricting their ability to compete on price while the illicit market faces no such restriction is a policy that benefits exactly one market participant: the unlicensed operator.

The Path Forward

New York has the infrastructure trajectory right. 519 stores growing toward 2,000 is the correct direction. The question is whether prices will compress fast enough to convert the density gains into capture gains.

The OCM's own cross-state data shows the answer: Colorado took 120 months for a 76% price decline. Massachusetts took 59 months for 69%. New York is 36 months in with a 15% decline. If the trajectory follows Massachusetts (the most relevant comparison — dense East Coast market, high cost of living, similar illicit competition), New York won't reach capture-driving price levels ($5-6/g) until 2028-2029 at the earliest.

The variables that could accelerate this: indoor cultivation licensing (50 new indoor cultivators licensed in 2024), supply chain maturation as the 200,000+ pounds of cultivator inventory works through the system, and continued retail expansion driving competition. The variables that could slow it: recommendation #11's discounting restrictions, continued enforcement limitations from court challenges, and municipal opt-outs maintaining artificial scarcity in high-population regions like Long Island.

What the CHS Literature Missed

New York's Office of Cannabis Management published 230 pages of official reporting across four documents in 2025 — a market report, an annual report, an enforcement report, and an equity report. The health and safety sections discuss overconsumption, dosing considerations, safe storage, traffic safety, pregnancy risks, youth prevention, and cannabis use disorder. The word "hyperemesis" appears zero times. "CHS" appears zero times. Across 230 pages of the most comprehensive state cannabis reporting in the country, the agency responsible for monitoring 2.77 million consumers did not identify CHS as a public health concern warranting discussion.

If CHS affected 17-33% of daily users as some clinical literature claims, New York's approximately 2.77 million estimated consumers would include 470,000-914,000 sufferers. That would be the single largest cannabis-related public health issue in the state by an order of magnitude — larger than impaired driving, youth consumption, and cannabis use disorder combined. It wouldn't be absent from 230 pages of health and safety reporting. It would be the headline.

Instead, the OCM's Chief Medical Officer frames the health mission around "evidence-based use." The state's education campaign — "Higher Education," launched April 2025 with 52.9 million media impressions — focuses on titration, understanding product effects, and responsible dosing. The agency's public health recommendations prioritize "dosing considerations" and "effective patient communication." This is the language of dose-related adverse events managed through education — not a chronic syndrome affecting a third of the consumer base. It's also consistent with what population-level psychiatric data suggests: that the vast majority of "cannabis psychosis" presentations are dosing events — transient paranoia from overconsumption that resolves with time and titration — rather than indicators of permanent psychiatric conditions. The absence of any psychosis-specific monitoring framework in OCM's 230 pages of reporting is consistent with an agency that treats adverse reactions as dose-management problems rather than psychiatric emergencies.

The Bottom Line

New York is simultaneously the best-documented and worst-performing major cannabis market in the country. The OCM publishes data that would be the envy of every other state regulator. The enforcement division has seized $143.8 million in illicit product. The equity program has achieved 55% SEE licensure. The retail footprint is scaling at one store per business day.

And the market captures 16% of demand at $10.61 per gram while over a thousand illicit storefronts sell comparable product at half the price.

The data is not the problem. The analysis is not the problem. The price is the problem. And price is a function of supply chain maturity, cultivation licensing, and time — none of which can be legislated into existence. New York is doing many things right. What it cannot do is skip the price compression cycle that mature markets have gone through before legal capture became meaningful. The question is whether policymakers will let the compression happen or try to regulate it away.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.